(Q33695747)

28 July 2017

1 reference

title

Novel strategies for pharmacotherapy of depression (English)

1 reference

28 July 2017

0 references

Maubach KA

1

1 reference

28 July 2017

Rupniak NM

series ordinal

2

1 reference

28 July 2017

Kramer MS

series ordinal

3

1 reference

28 July 2017

Hill RG

series ordinal

4

1 reference

28 July 2017

1 August 1999

1 reference

Current Opinion in Chemical Biology

28 July 2017

1 reference

28 July 2017

3

1 reference

28 July 2017

481-488

1 reference

28 July 2017

4

1 reference

Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

The treatment of depressive states with G 22355 (imipramine hydrochloride).

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Pharmacology of antidepressants--characteristics of the ideal drug

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

A large open-label study of venlafaxine in depressed outpatients by community-based physicians.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

A meta-analysis of the effects of venlafaxine on anxiety associated with depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Buspirone augmentation of antidepressant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Effects of SSRIs on sexual function: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Buspirone, gepirone, ipsapirone, and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-s schedule when compared with 5-HTP and diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

BIMT 17: a putative antidepressant with a fast onset of action?

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Altered nociception, analgesia and aggression in mice lacking the receptor for substance P

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

The role of corticotropin releasing factor in depressive illness: a critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

The role of corticotropin-releasing factor in depression and anxiety disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Chronic antidepressant treatment increases enkephalin levels in n. accumbens and striatum of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Imipramine inhibits soluble enkephalin-degrading aminopeptidase activity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Effects of fluoxetine administration on mu-opoid receptor immunostaining in the rat forebrain.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Dynorphin A increases substance P release from trigeminal primary afferent C-fibers.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Buprenorphine treatment of refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Dehydroepiandrosterone (DHEA) treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Neurotrophins and depression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

Novel therapeutic approaches beyond the serotonin receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980070-2

7 January 2021

10.1016/S1367-5931(99)80070-2

Identifiers

DOI

1 reference

28 July 2017

1 reference